RT Journal Article
SR Electronic
T1 A 12-year polysomnographic study in Huntington’s: sleep problems predict disease onset and severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.31.24311309
DO 10.1101/2024.07.31.24311309
A1 Voysey, Zanna J.
A1 Goodman, Anna OG.
A1 Rogers, Lorraine
A1 Holbrook, Jonathan A.
A1 Lazar, Alpar S.
A1 Barker, Roger A.
YR 2024
UL http://medrxiv.org/content/early/2024/08/02/2024.07.31.24311309.abstract
AB Increasing evidence suggests that the sleep pathology associated with neurodegenerative diseases can in turn exacerbate both the cognitive deficits and underlying pathobiology of these conditions. Treating sleep may therefore bear significant, even disease-modifying, potential for these conditions, but how best and when to do so remains undetermined.Huntington’s Disease (HD), by virtue of being an autosomal-dominant neurodegenerative disease presenting in mid-life, presents a key ‘model’ condition through which to advance this field. To date, however, there has been no clinical longitudinal study of sleep abnormalities in HD, and no robust interrogation of their association with disease onset, cognitive deficits and markers of disease activity. Here we present the first such study.HD gene carriers (n=28) and age- and sex-matched controls (n=21) were studied at baseline and 10- and 12-year follow up. All HD gene carriers were premanifest at baseline, and were stratified at follow up into prodromal/manifest and premanifest groups. Sleep abnormalities were assessed through two-night inpatient polysomnography (PSG) and two-week domiciliary actigraphy, and their association was explored against i)validated cognitive and affective outcomes (Montreal Cognitive Assessment, Trail A/B task, Symbol Digit Modalities Task [SDMT], Hopkins Verbal Learning Task [HVLT], Montgomery-Asberg Depression Rating Scale [MADRS]) and ii)serum neurofilament-light (NfL) levels. Statistical analysis incorporated cross-sectional ANCOVA, longitudinal repeated measures linear models and regressions adjusted for multiple confounders including disease stage.15 HD gene carriers phenoconverted to prodromal/early manifest HD by study completion. At follow-up, these gene carriers showed more frequent sleep stage changes (p=<0.001,ƞp2=0.62) and higher levels of sleep maintenance insomnia (p=0.002,ƞp2=0.52). The latter finding was corroborated by nocturnal motor activity patterns on follow-up actigraphy (p=0.004,ƞp2=0.32).Greater sleep maintenance insomnia was associated with greater cognitive deficits (Trail A p=<0.001,R²=0.78;SDMT p=0.008,R²=0.63;Trail B p=0.013,R²=0.60) and higher levels of NfL (p=0.015,R²=0.39).Longitudinal modelling suggested that sleep stage instability accrues from the early premanifest phase, whereas sleep maintenance insomnia emerges closer to phenoconversion. Baseline sleep stage instability was able to discriminate those who phenoconverted within the study period from those who remained premanifest (area under curve=0.81,p=0.024).These results demonstrate that the key sleep abnormalities of premanifest/early HD are sleep stage instability and sleep maintenance insomnia, and suggest that the former bears value in predicting disease onset, while the latter is associated with greater disease activity and cognitive deficits. Intervention studies to interrogate causation within this association could not only benefit patients with HD, but also help provide fundamental proof-of-concept findings for the wider sleep-neurodegeneration field.Competing Interest StatementThe authors have declared no competing interest.Funding StatementZJ Voysey was funded by an Association of British Neurologists/Guarantors of Brain Clinical Research Fellowship (G104701). JA Holbrook was supported by the Centre Parkinson Plus Grant and Cure Parkinsons Trust. AS Lazar was supported by funding from the UKRI (ES/W006367/1) and The Wellcome Trust (207799_Z_17_Z). The study was additionally supported by the CHDI Foundation (CHDI‐RG50786), the NIHR (BRC‐RG64473) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), the Wellcome Trust (203151/Z/16/Z, 203151/A/16/Z) and the UKRI Medical Research Council (MC_PC_17230). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of Cambridge Central, along with the Health Research Authority, gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes